Osteoporosis
Conference Coverage
How to rule out secondary causes of osteoporosis
ESTES PARK, COLO. – Is a patient’s osteoporosis secondary to another condition? Figure it out with an “incredibly cost effective” lab workup.
Conference Coverage
Anabolic agents for osteoporosis have limited role so far
Parathyroid hormone and parathyroid hormone-related protein analogs show promise for osteoporosis, but, for now, they’re reserved for the most...
Conference Coverage
Tool indicates fracture risk after HSCT
MADRID – Bone health could be assessed earlier using FRAX, ideally at or before the time of the transplant.
Conference Coverage
Meta-analysis: Bisphosphonates mitigate glucocorticoid-induced bone loss
MADRID – The drugs examined were ibandronate, alendronate, risedronate, etidronate, and clodronate.
Conference Coverage
Romosozumab cuts new vertebral fracture risk by 73%, but safety data are concerning
MADRID – Investigational bone-building drug looks promising, but safety concerns emerge.
From the Journals
Updated osteoporosis guideline advocates bisphosphonates, nixes estrogens
Even though well-designed, randomized controlled trials amply demonstrate the effectiveness of bisphosphonates in preventing fractures,...
Conference Coverage
New evidence bisphosphonates may prevent OA
LAS VEGAS – A favorable signal is seen in the Osteoarthritis Initiative.
News
FDA approves abaloparatide for postmenopausal osteoporosis
The Food and Drug Administration has approved abaloparatide (Tymlos) for postmenopausal women with osteoporosis at high risk for fracture.
News from the FDA/CDC
Just the FRAX: National fracture risks estimated
A risk-estimating algorithm puts 10-year probability of major osteoporotic fracture at 5.3% in adults aged 40 years and over.
From the Journals
Study shows no adverse events with long-term denosumab in postmenopausal women
Denosumab, taken long term, is not linked with any adverse events, an analysis of the participants in the FREEDOM trial showed.
Feature
New guidance: Bone health is front and center in functional hypothalamic amenorrhea care
Diagnosing can be tricky, but several viable treatment options exist.